CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

GlobeNewswire Clinical Studies
Original article

Eleva separates Bryotechnology platform and clinical-stage Factor H biotherapeutic into independent companies

Factor H biotherapeuticNeutral
AI Analysis

Summary

Eleva separates its Bryotechnology platform and clinical-stage Factor H biotherapeutic into independent companies through a corporate restructuring.

Importance:4/10
Sentiment:
0.00
corporate restructuringspin-offplatform separationFactor H

Read the original article

Published by GlobeNewswire Clinical Studies on September 15, 2026 6:30 AM

Read Original